Form 4: Director Randall Livingston Receives PACB Stock Options

Pacific Biosciences director Randall S. Livingston was granted 223,492 stock options as part of standard equity compensation.

Summary

• Director Randall S. Livingston received a grant of 223,492 stock options on June 3, 2026.
• The options have an exercise price of $1.58 per share.
• The options are set to expire on June 3, 2036.
• Vesting occurs monthly over a one-year period, contingent on continued service as a director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Granting of options results in potential future dilution for existing shareholders.

Risks

• Future dilution of equity if options are exercised.
• Market price volatility affecting the value of the granted options.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a standard disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent, though investors should monitor total dilution levels.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard corporate governance practices for mid-cap biotechnology firms.
• Vesting schedules of one year for director equity are common in the industry to ensure board stability.

Stakeholder Impact

• Minor potential dilution for existing shareholders upon future exercise of options.

Next Steps

• Director to continue service to satisfy vesting requirements.

Key Dates

Keywords

PACB, Pacific Biosciences, Form 4, Insider Trading, Stock Options, Director Compensation